Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
OpenAI Nears Astra AI Model Launch With Safety Focus 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Add as a preferred source on Google
Heidelberg, Germany, March 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company's AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.
Poster Presentation
Abstract: Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)
Session: PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Monday, April 16, 2018 1:00 PM - 5:00 PM (CT)
Location: McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL
Full abstract of the presentation can be accessed on the AACR website at www.aacr.org
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
